Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial

Abstract

Purpose

Investigate safety and tolerability of adrecizumab, a humanized monoclonal adrenomedullin antibody, in septic shock patients with high adrenomedullin.

Methods

Phase-2a, double-blind, randomized, placebo-controlled biomarker-guided trial with a single infusion of adrecizumab (2 or 4 mg/kg b.w.) compared to placebo. Patients with adrenomedullin above 70 pg/mL, < 12 h of vasopressor start for septic shock were eligible. Randomization was 1:1:2. Primary safety (90-day mortality, treatment emergent adverse events (TEAE)) and tolerability (drug interruption, hemodynamics) endpoints were recorded. Efficacy endpoints included the Sepsis Support Index (SSI, reflecting ventilator- and shock-free days alive), change in Sequential-related Organ Failure Assessment (SOFA) and 28-day mortality.

Results

301 patients were enrolled (median time of 8.5 h after vasopressor start). Adrecizumab was well tolerated (one interruption, no hemodynamic alteration) with no differences in frequency and severity in TEAEs between treatment arms (TEAE of grade 3 or higher: 70.5% in the adrecizumab group and 71.1% in the placebo group) nor in 90-day mortality. Difference in change in SSI between adrecizumab and placebo was 0.72 (CI −1.93–0.49, p = 0.24). Among various secondary endpoints, delta SOFA score (defined as maximum versus minimum SOFA) was more pronounced in the adrecizumab combined group compared to placebo [difference at 0.76 (95% CI 0.18–1.35); p = 0.007]. 28-day mortality in the adrecizumab group was 23.9% and 27.7% in placebo with a hazard ratio of 0.84 (95% confidence interval 0.53–1.31, log-rank p = 0.44).

Conclusions

Overall, we successfully completed a randomized trial evaluating selecting patients for enrolment who had a disease-related biomarker. There were no overt signals of harm with using two doses of the adrenomedullin antibody adrecizumab; however, further randomized controlled trials are required to confirm efficacy and safety of this agent in septic shock patients.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00134-021-06537-5.

Take-home message

The primary endpoint of AdrenOSS-2 was achieved as adrecizumab was well tolerated and showed a favorable safety profile. In this biomarker-guided trial, the mode of action was confirmed: adrecizumab rapidly increased plasma levels of bioactive adrenomedullin, a key hormone restoring and maintaining vascular integrity and endothelial function.

Introduction

Septic shock is a subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality [1]. According to recent studies, vascular endothelial hyperpermeability and edema typically develop very early and involve the global endothelial barrier [2]. Adrenomedullin (ADM) is essential for endothelial barrier development and stability [3]. In human sepsis, various processes stimulate ADM secretion [4–6]. Bioactive ADM (bio-ADM) is an active, short-lived circulating peptide that derives from the prohormone fragment proADM. Upon admission to the intensive care unit (ICU), sepsis patients who are prone to develop septic shock, present elevated plasma levels of bio-ADM, the latter being associated with severe (multiple) organ dysfunction and an elevated mortality risk [7–9]. This bio-ADM increase in plasma concentration has been interpreted as both a bystander of endothelial dysfunction and a counterregulatory response to the impairment of vascular integrity [10]. Pre-clinical models of septic shock showed that modulating the ADM pathway with the high-affinity, non-neutralizing monoclonal anti-ADM antibody adrecizumab, improved endothelial homeostasis, organ function and survival [11–14]. Thus, strategies aiming at preventing disruption or at repairing endothelial cell–cell junctions may provide septic shock patients the opportunity to mitigate organ dysfunction and thereby to improve their outcome.

Conducting research in critically ill patient populations is challenging. Due to the heterogeneity of the populations, experts recently advised the use of advanced trial designs to assess and promote “personalized” therapies [15, 16]. Such trial designs combine biomarker-guided enrichment of enrolled patients to reduce heterogeneity and biomarker-guided therapy to enhance likelihood of success for novel therapies. The latter are based on the biological plausibility for the new compound to exert therapeutic efficacy.

We now report the results of the AdrenOSS-2 trial, a phase 2a, randomized, double-blind, placebo-controlled trial using bio-ADM-guided enrichment and therapy with the non-neutralizing anti-ADM antibody adrecizumab in early septic shock patients.

Methods

Design

This was a double-blind, placebo-controlled, randomized, multicenter, biomarker-guided and dose-finding phase 2a trial to investigate the safety, tolerability, efficacy and pharmacokinetics of adrecizumab in patients with early septic shock and elevated bio-ADM levels. The trial was conducted in thirty hospitals with medical, surgical and/or mixed ICUs in Belgium, France, Germany and the Netherlands. Further details on the trial setting and design were reported earlier [17]. Of note, preliminary results were presented at the ISICEM meeting.

Ethical considerations

The trial procedures and the informed consent form (ICF) process were approved by the respective independent ethics committee (IEC) following international standards and national requirements of each participating country. The AdrenOSS-2 trial was registered at Clinical trial.gov (NCT03085758).

Participants

Patients (≥ 18 years) at the early phase of septic shock who met the inclusion- and none of the exclusion criteria were enrolled. Main inclusion criteria were elevated bio-ADM values (> 70 pg/mL), in the early phase of septic shock, defined as start of vasopressor therapy less than 12 h before inclusion. A full list of inclusion and exclusion criteria can be found in the electronic supplementary material. After a written informed consent form was provided by the patient or his/her legal representative and when plasma bio-ADM concentration was > 70 pg/mL (Sphingotest^® bio-ADM^®, SphingoTec GmbH, Hennigsdorf, Germany), a clinical coordination center (CCC) confirmed patient eligibility for enrolment in the trial. All trial related data was captured in a pseudonymized way.

For bio-ADM measures, blood was withdrawn in EDTA tubes and immediately centrifuged at room temperature. Bio-ADM measures followed 3 phases that usually took less than 2 h: (1) reconstitute controls and tracer, (2) incubation for 1 h at 22 °C and (3) wash and measurement of the luminescence signals by the microplate Centro LB960. For each patient, Bio-ADM was performed, once at screening, locally either in the laboratory or directly on ICU by trained staff or, for Paris and surrounding region, by a central laboratory available 24/7, in Lariboisière hospital. Of note, no bio-ADM measure was allowed after the initiation of study drug. The threshold of 70 pg/mL on bio-ADM was selected based on increased risk of bad outcome described in previous studies [8].

Intervention

Patients were randomly assigned in a 1:1:2 ratio to either treatment arm A (adrecizumab 2 mg/kg body weight (b.w.)), treatment arm B (adrecizumab 4 mg/kg b.w.) or placebo, respectively. Patients received the assigned trial medication in a single intravenous infusion (duration: approximately 1 h) [17].

A nested pharmacokinetic (PK) sub-study was performed in a subgroup of 56 patients for whom the complete dataset of all 7 samples were available, with blood sampling from Day 1 to Day 7 and on Day 28 to determine the pharmacokinetic profile of adrecizumab. Blood samples were taken at fixed time points prior to and following trial medication administration (see trial protocol at ClinicalTrials.gov Identifier: NCT03085758). The first blood sample was taken more than 20 h after initiation of studied therapy in three patients that were excluded from this analysis. Thus, final analysis was based on 53 patients.

Outcome measures

The primary objective of this study was to investigate safety and tolerability of adrecizumab. Endpoints of safety were frequency and severity of adverse events (AEs, recorded thoroughly starting from informed consent form signature) and treatment emergent adverse events (TEAEs) and 90-day mortality and endpoints of tolerability were blood pressure, heart rate, and episodes of interruption of infusion. Secondary objectives were clinical efficacy and pharmacokinetics of adrecizumab. Key efficacy endpoint was the Sepsis Support Index (SSI) defined as days with organ support (hemodynamic, renal or respiratory) or death within 14-day follow-up, achieving a combined endpoint of organ dysfunction and death. A detailed description on how to calculate the Index is described by Geven et al. [17] and in the electronic supplementary material. Other secondary efficacy endpoints included Day 28 mortality, change in SOFA score (assessed every 24 h during the first week), duration of ICU stay, changes of vital signs [e.g. mean arterial pressure (MAP) and heart rate (HR)], as well as other parameters collected during ICU stay such as fluid balance, partial pressure of oxygen/fraction of inspired oxygen (PaO₂/FiO₂), creatinine, procalcitonin (PCT) level, duration of vasopressor use and Quality of Life (Euro-QoL-5). In the nested pharmacokinetic sub-study, the following parameters were determined: peak observed maximum plasma concentrations (C_max), time to C_max (t_max), systemic exposure, area under the curve (AUC), volume of distribution (V), systemic clearance (CL) and elimination half-life (t½).

Data analyses and statistics

Safety and tolerability endpoints were reported and efficacy endpoints were analyzed in all patients who were randomized to a treatment group (Intent-to-treat (ITT) analysis). In the ITT data set, all patients provided informed consent and received the trial medication. The primary analysis included the comparison of the combined adrecizumab doses to placebo [17]. The per-protocol (PP) analysis included all patients who, in addition, received the trial medication according to the protocol with minor deviations only and satisfied all major entry criteria. For the pharmacokinetic analysis set geometric means and standard deviation (SD) were calculated, for each time point and dose, if 2/3 of the values were above the lower limit of quantification and if n was greater than two. Demographic and medical background data, safety variables and secondary endpoints are to be analyzed by means of descriptive and exploratory methods. Continuous data were analyzed by number of patients, median and interquartile range. Discrete data (i.e. metric, but non-continuous data, like SSI, SOFA score, and Quality of Life), were analyzed by number of patients, arithmetic mean and SD. Exploratory comparisons for both continuous and discrete data were performed using the Kruskal–Wallis test. Categorial variables are summarized category-wise giving numbers and percentages, and compared using the Chi² test for contingency tables. Since antibodies were given in excess in both treatment arms (2 and 4 mg/kg), data were combined for efficacy analysis. The distribution of the SSI in placebo and the combined adrecizumab arms was compared via the Kolmogorov–Smirnov test and the empirical distribution function was used for comparison. The delta SSI was estimated and tested using both the t test and the Kruskal–Wallis test with the Hodges–Lehmann estimator. The log-rank test was chosen for showing differences in mortality rates among treatment groups, and Kaplan–Meier plots were used for illustration. Unadjusted and adjusted hazard ratios (HR) were estimated via Cox proportional hazard models. HR were adjusted for possible differences in baseline severity (pre-Investigational Medicinal Product (pre-IMP) SOFA and APACHE score, and pre-IMP bio-ADM and lactate), as well as for baseline characteristics that differed between treatment arms. Adjusted HR were derived by including the respective co-variable into a multivariable Cox regression model, together with the treatment effect. Imputation for SOFA score were performed for patients discharged or dead on day 2–7 after enrolment (see electronic supplementary material) (Grooth et al. [18]). Note that these patients are not “missing at random”, and therefore cannot be treated like other missing data points. No additional imputations were made for the primary analysis reported neither for other missing SOFA scores nor for any SSI. All reported p values are 2-sided. p values below 0.05 were considered significant. This phase 2 trial was not powered to prove clinical efficacy. No confirmative testing was considered, and as secondary outcome parameters were in part correlated, especially for variables evaluated at multiple time points, reported p values were not corrected for multiple testing. The sample size calculation was based on simulation of real patient data, described in the method paper [17] and in the electronic supplementary material. Statistical analyses were performed using SAS version 9.3, and R version 3.4.3 (http://www.r-project.org). The calculation of the PK parameters was performed using Phoenix^® WinNonlin version 8.1.

Results

Patients and study treatment

Enrollment of patients started with the first patient being randomized on December 8, 2017. The last patient was randomized on September 25, 2019. Altogether, 459 patients were screened. Out of these 158 were non-eligible and, therefore, not randomized (n = 91 with bio-ADM < 70 pg/mL; n = 67 for failing with regard to other inclusion/exclusion criteria). In total, 301 patients were randomized to either placebo (n = 152), 2 mg/kg (n = 72) or 4 mg/kg adrecizumab (n = 77), defining the ITT population (Fig. 1). For the PP analysis, seven patients were excluded, see Supplement Table 2 for details.

Fig. 1.

Patient flowchart. Overall, in 30 sites in four European countries, 459 patients were screened, of which 301 were eligible and randomized (intention-to-treat (ITT) population). Five patients withdrew consent during follow-up and five were lost to follow-up. In both cases, data from these patients was included to maximum extent. For the per-protocol (PP) analysis, seven patients had major protocol deviations, and were excluded and analyses were performed on 294 patients (see Supplement Table 2 for details)

AdrenOSS-2 showed that all requirements, including local bio-ADM measures, were duable in early septic shock, allowing a study drug initiation 8.50 [5.83–11.00] hours after onset of shock (8.67 [5.58–10.95] hours in the adrecizumab group and 8.38 [6–10.87] hours in the placebo group). Baseline characteristics are shown in Table 1 and were broadly balanced among all groups in terms of age, mean body temperature, MAP and respiratory rate. Sources of infection were predominantly abdomen (21.6%), lung (20.9%) or urinary tract (17.9%).

Table 1.

Patient characteristics for all patients randomized (ITT, n = 301)

Variable	n	Adrecizumab 2 mg/kg (n = 72)	Adrecizumab 4 mg/kg (n = 77)	Placebo (n = 152)	Adrecizumab (n = 149)
Age (years)	301	68 [59–75]	71 [65–77]	71 [60–78]	71 [62–76]
Gender female	301	27 (37.5)	24 (31.2)	66 (43.4)	51 (34.2)
BMI (kg/m2)	299 a	25.2 [22.9–28.1]	25.6 [23.4–29.5]	26.5 [24.1–30.4]	25.3 [23.2–29]
Parameters at inclusion
Temperature (°C)	284 a	36.9 [36.3–37.6]	37 [36.2–37.7]	37.1 [36.5–37.6]	37 [36.25–37.7]
HR (bpm)	301	102 [86–123]	97 [83–111]	96 [79–110]	98 [84–115]
MAP (mmHg)	301	72 [66–80.25]	70 [66–76]	71 [66–79]	71 [66–78]
SOFA (points)	254 a	11 [7–11]	10 [7–11]	9 [7.75–11.25]	10 [7–11]
APACHE II (points)	272	32 [29–34]	33 [28–36]	33 [29–36]	32 [28.75–35]
Origin of sepsisb	301
Lung	63	14 (19.4)	17 (22.1)	32 (21.1)	31 (20.8)
Peritonitis	65	12 (16.7)	17 (22.1)	36 (23.7)	29 (19.5)
Urinary tract	54	18 (25)	10 (13)	26 (17.1)	28 (18.8)
Skin and soft tissue	24	2 (2.8)	8 (10.4)	14 (9.2)	10 (6.7)
Others	95	26 (36.1)	25 (32.5)	44 (28.9)	51 (34.2)
Co-morbiditiesc
Chronic heart failure	301	9 (12.5)	8 (10.4)	15 (9.9)	17 (11.4)
Hypertension	301	35 (48.6)	45 (58.4)	101 (66.4)	80 (53.7)
Biomarker
Bio-ADM, local (pg/mL)	301	210.8 [127.1–318.4]	203.2 [131.9–372.6]	199.9 [120–300.1]	205.1 [128.2–339.3]
Treatment on admissionc
Time ICU admission to studied therapies (days)	301	0.36 [0.23–0.56]	0.43 [0.26–0.58]	0.31 [0.22–0.51]	0.42 [0.25–0.57]
Time between initiation of vasopressor and initiation of studied therapies (h)	301	7.48 [5.5–10.49]	9.63 [5.67–11.17]	8.38 [6–10.87]	8.67 [5.58–10.95]
Days on vasopressor, 14 days (days)	297	4.14 (2.94)	5.09 (3.82)	4.63 (3.44)	4.68 (3.86)
Days on vasopressor, 28 days (days)	297	4.82 (4.65)	5.97 (5.54)	5.41 (5.14)	5.27 (5.11)

Median and interquartile range, mean and SD or counts and percentages are given. p values from Chi² or Kruskal–Wallis test, as appropriate

IQR interquartile ranges; BMI Body Mass Index; HR heart rate; bpm beats per minute; MAP mean arterial pressure; mmHg millimetres of Mercury; bio-ADM biologically active adrenomedullin; pg/mL picogram per milliliter; MR-proADM circulating mid-regional proADM; nmol/L nano-mol per liter; ng/mL nano-gramme per millilitre; SOFA Sepsis-related Organ Failure Assessment

^aMissing values

^bOnly the top three origins of sepsis are presented

^cOnly a selection is presented here

SOFA and APACHE II scores were typical for a septic shock population at baseline: 9 [7–10] and 33 [29–36] (median [IQR]) in the placebo group and 10 [7–11] and 32 [29–35] in the combined Adrecizumab 2 and 4 mg/kg arms, respectively. (Table 1).

Safety and tolerability of combined adrecizumab dose-groups

Results of the primary safety (AEs and TEAEs) analysis are summarized in Fig. 2. The incidence of AEs and TEAEs was similar among the three studied arms. A total of 284/301 (97.3%) patients experienced at least one TEAE (details by primary organ system class are given in the electronic supplementary material. Overall, 105 out of 149 patients reported TEAEs of grade 3 or higher (70.5%) in the combined adrecizumab group (2 and 4 mg/kg), and 108/152 (71.1%) patients in the placebo group. A total of 25 patients (8.3%) reported a TEAE related to the drug administration overall: 12 (8.3%) in the combined adrecizumab group and 13 (8.6%) in the placebo group. For one patient randomized to the 4 mg/kg adrecizumab group, the infusion was stopped prematurely due to a cardiac repolarization abnormality, observed during electrocardiography. Patient survival at Day 90 between the combined adrecizumab group and placebo was similar.

Fig. 2.

Adverse events (AE) and Treatment Emergent Adverse Events (TEAEs) by treatment arm in all patients randomized (ITT, n = 301). TEAEs were AEs not present at baseline, or AEs that worsened after start of treatment even if they were present at baseline. AEs (any, serious or death) or TEAEs were similar, between patients randomized to Adrecizumab and placebo. *TEAE, grade 3–5  all severe events according to Common Terminology Criteria for Adverse Events (CTCAE) classification; TEAE, serious  all serious events; TEAE, death  all events that led to death; TEAE, related all events that were categorized as related to Adrecizumab

Concerning tolerability, infusion was stopped prematurely in one patient of the adrecizumab 4 mg/kg group and similar changes in arterial pressure or heart rate were seen over time between patients randomized to adrecizumab combined or placebo groups (Supplement Fig. 2).

Efficacy of the combined adrecizumab group

No significant treatment effect of the combined adrecizumab arms on the SSI within 14 days follow-up was observed, the difference in change in SSI between adrecizumab and placebo was 0.72 (95% CI −1.93–0.49, p = 0.242) based on the t test and 0 (95% CI 0–0, p = 0.32) based on Hodges–Lehmann. The SSI was below 14 in 60.3% of patients treated with placebo and in 58.9% in patients treated with adrecizumab (Fig. 3A). Results were similar for the SSI within the 28 days follow-up. Looking at each component separately, the respiratory, renal, cardiac, as well as the mortality component showed no differences between treatment arms. See Supplement Table 4A and B for full details.

Fig. 3.

Efficacy endpoints in the ITT population—SSI and SOFA score change. A Mean and 95% CI of Sepsis Support Index (SSI) with 14 days follow-up, Adrecizumab combined (blue) and placebo (red) for ITT (p = 0.32, Kruskal–Wallis test, and p = 0.45, two-sample Kolmogorov–Smirnov test). B SOFA score change (points) starting prior Adrecizumab/placebo administration (pre-Investigational Medicinal Products (IMP)) (mean with 95% CI) for ITT (n = 254 with pre-IMP SOFA score available). For each time point the maximum number of patients with available SOFA score data was used. All time points show the same directionality. *p < 0.05 for 24 h change. As the number of missing patients differed between time points, post hoc sensitivity analysis were performed and results shown in supplement Fig. 6

Among various secondary endpoints, Fig. 3B shows that the delta SOFA score (defined as maximum versus minimum SOFA during the first 144 h after randomization, available in only n = 280 due to missings) was more pronounced in the adrecizumab combined group compared to placebo (mean (SD) 4.05 (2.41) vs. 3.29 (2.56); difference in the delta was 0.76 (95% CI 0.18–1.35); p = 0.007. The difference in the change in SOFA between adrecizumab combined and placebo (available only in up to n = 239 patients due to missings) was 1.0 SOFA score points (mean, 95% CI 0.0–2.0), 0.8 (−0.5–2.2), 0.7 (−0.9–2.2), 1.0 (−0.6–2.7), 0.6 (−1.1–2.5) and 0.5 (−1.5–2.4) for the change from pre-IMP to 24, 48, 72, 96, 120 and 144 h, respectively (Supplement Table 4A). Sensitivity analysis and histograms are shown in supplement Figs. 6 & 7.

The 28-day mortality was 23.9% and 27.7% in the adrecizumab combined and placebo groups, respectively, with the unadjusted HR (95% CI) of 0.84 [0.53–1.31], log-rank p = 0.44 for adrecizumab combined (Fig. 4A, B). Results after adjustment for baseline severity (pre-IMP SOFA score or bio-ADM) are shown in Supplement Table 5. Exploratory interaction analysis for 28-day mortality did not indicate a further need for stratification based on initial bio-ADM beyond the initial inclusion criteria (interaction term p value = 0.25, model including treatment, baseline bio-ADM and the interaction term), nor on severity scores (p = 0.96 and 0.75 for SOFA score or APACHE II score, respectively). On short-term mortality, 32 (21.3%) patients died in the placebo group and 25 (16.8%) in the adrecizumab combined group within the first 14 days, while from day 15–28, in both placebo and adrecizumab combined group, another 10 patients died (6.6% and 6.7%, respectively, see Supplement Table 4B for further details).

Fig. 4.

Efficacy endpoints in the ITT population—hazard ratios (HR) and survival rates. A HR with 95%-CI for 28-day mortality (n = 301) Combined = both doses of adrecizumab + the placebo group as control; 2 mg/kg = treatment arm with 2 mg/kg adrecizumab + the placebo group as control; 4 mg/kg = treatment arm with 4 mg/kg adrecizumab + the placebo group as control. Treatment effects were adjusted for initial severity: baseline bio-ADM (bio-ADM adj.); pre-IMP SOFA score (Score prior adrecizumab administration; SOFA adj.)—to rule out baseline differences affecting the observed mortality reduction. B Kaplan–Meier plot for 28-day mortality: adrecizumab combined and placebo (n = 301)

Concerning quality of life assessments, change of the Visual Analogue Scale (VAS) from ICU discharge to 90-day follow-up: 16.5 ± 22.5 compared to 7.6 ± 27.5 in the placebo group (difference of 8.9 (95% CI 0.2–17.6); p = 0.052). Mean duration of vasopressor therapy and average fluid balance were non-significant. See Supplement Table 4A for further details.

Per-protocol analyses

Seven patients had to be excluded for the PP analysis, details are listed in Supplement Table 2. Patient characteristics for the PP population can be found in Supplement Table 3. Safety results were similar to those in ITT (Supplement Table 1), and efficacy results tended to move in favor of adrecizumab (see Supplement Figs. 3–5 and Supplement Table 4B for details).

Dose effect

With respect to safety, no apparent dosing effect could be observed: In the adrecizumab 2 mg/kg group, 51/72 (70.8%) patients and in the adrecizumab 4 mg/kg group, 54/77 (70.1%) patients experienced a TEAEs of grade 3 or higher. TEAE’s related to the drug administration were reported in in 6 (8.3%) patients in the adrecizumab 2 mg/kg group and 6 (7.8%) patients in the adrecizumab 4 mg/kg group (Fig. 2).

Pharmacokinetics

In the pharmacokinetic study data set (n = 53 for whom demographics were similar to the entire studied population, (see electronic supplementary material), the mean peak plasma concentrations (C_max) for free adrecizumab in patients treated with 2 mg/kg adrecizumab was 38.2 µg/mL (SD 10.4) and 86.9 µg/mL (SD 22.2) in 4 mg/kg group. Terminal half-life was similar in the two adrecizumab-treated groups: 206 (SD 44) hours versus 178 (SD 44) hours in adrecizumab 2 mg/kg and 4 mg/kg, respectively. As the bio-ADM concentration slowly decreased, the levels of circulating MR-proADM, the stable fragment of pro-ADM, were similar among the three groups (Fig. 5).

Fig. 5.

Pharmacokinetics by time of blood draw and treatment arm, A geometric means (± Standard Deviation (SD) of free adrecizumab in n = 53 patients (eligible PK analysis set), B means of bio-ADM (± standard error of the mean (SEM)) (all available samples), and C MR-proADM (± standard error of the mean) (all available samples)

Discussion

The AdrenOSS-2 trial is the first randomized controlled trial in the ICU to be completed using a study-specific biomarker related to the proposed mechanism of action to select trial participants. Septic shock patients suffering from endothelial barrier dysfunction as manifested by elevated bio-ADM levels were randomized for the treatment with the anti-ADM antibody adrecizumab, modulating the ADM pathway, or placebo in a phase II clinical trial. Adrecizumab at both tested doses (2 or 4 mg/kg) achieved the primary endpoint, as it was well tolerated and revealed a favorable safety profile as the prevalence of all recorded safety parameters were similar between adrecizumab and placebo groups.

Adrecizumab as a high-affinity, but non-neutralizing antibody is thought to enhance the endogenous plasma bio-ADM activity, exerting beneficial effects on the endothelium, while at the same time limiting the unfavorable effects of bio-ADM on the vascular smooth muscle cells [10]. Increase in circulating bio-ADM might result from (a) hypothesized partial redistribution of bio-ADM from the interstitium—where it may trigger vasodilation via the vascular smooth muscle cells—towards the lumen of the vessels, and (b) the reduction of proteolytic degradation of plasma bio-ADM [10]. In agreement with confinement in the circulation, in the present study, we observed a higher initial concentration (C_max) of adrecizumab in the 4 mg/kg group compared to 2 mg/kg and adrecizumab exhibited a terminal elimination half-life of 7–8 days. Based on the present result, further clinical steps will use 4 mg/kg of adrecizumab. In addition, we confirmed a dose-dependent adrecizumab-induced increase of plasma bio-ADM with no change in MR-proADM, demonstrating that the bio-ADM increase is not due to de novo synthesis, as observed previously in phase I clinical trials [19]. As other therapeutic antibodies and proteins also show a similar accelerated clearance in sepsis or severe inflammatory disease, a general mechanism of enhanced elimination is obvious and this could be, at least partially, an accelerated intracellular degradation. The concentration of free adrecizumab might be reduced by other mechanisms as well, including a disease-related augmented production rate of its antigen ligand bio-ADM.

AdrenOSS-2 also explored signals of clinical efficacy of adrecizumab in this biomarker-guided trial. The SSI, a novel composite endpoint aiming at integrating both, mortality and organ dysfunction [17], showed no difference among studied groups while a rapid and consistent reduction of SOFA score was observed in adrecizumab-treated patients compared to placebo. In adrenOSS-2, SSI was similar in some aspects to changes in SOFA score, though differed in others, including the weight of mortality. In one hand, the advantage of the SSI was that it relied on fewer data points than the SOFA score, and was, therefore, easier to record. In the other hand, SOFA score typically has missing data in up to 10–20% of patients on each specific day despite efforts to get complete recordings. Though post hoc sensitivity analysis showed similar results, missings and methods to handle them confer important bias. Another difference between the 2 scores is that, change in SOFA took into account the severity of a patient on inclusion, therefore, measured relative change while SSI can only observe absolute change per treatment group. Finally, the SSI incorporates three organ classes, and mortality, in a dichotomous count, while the SOFA score incorporates six organ classes and each can change on a scale from 0 to 4. Accordingly, based on AdrenOSS-2 trial and on recent recommendations to improve clinical trial design in critical care [16], the next phase IIb/III of the adrecizumab program, named ENCOURAGE, will assess adrecizumab (4 mg/kg) in septic shock patients, very early after initiation of vasopressor, combining predictive and prognostic enrichment strategies and targeting benefits on 28-day mortality and change in SOFA with special attention in preventing missing values.

The limitations of our trial include the lack of power to detect clinically important differences or to define dose response. Both doses turned out to be safe with a good tolerability profile, therefore both doses might be considered for future biomarker-guided trials. Further improvement may be achieved by enrichment of the patient group that may benefit most and an optimized treatment window for septic shock to further enhance the survival rate. Our study therapy was initiated within the first 12 h after detection of septic shock, a time-span found to be decisive for initiation of specific therapy. Secondary endpoints were not adjusted for multiple testing, therefore some results may have become significant by chance and results need replication/confirmation.

In conclusion, AdrenOSS-2 demonstrated that the novel trial design with a personalized approach applying a pathway-related biomarker was duable, even in the stringent ICU setting. Furthermore, this contemporary biomarker-guided phase 2 trial in septic shock demonstrated that there were no overt signals of harm and rather good tolerance with the use of adrecizumab. Benefits should yet be assessed in future biomarker-designed trials.

Supplementary Information

Below is the link to the electronic supplementary material.

Funding

The AdrenOSS-2 study was funded by Adrenomed AG.

Declarations

Conflicts of interest

P-F L received fees as a coordinator of the CCC. PP reports travel and consultancy reimbursement from Adrenomed, SphingoTec, 4TEEN4, AM-Pharma, Baxter, EBI. XW was part of the Clinical Coordinating Center assessing patient’s eligibility. No other conflict of interest. FM has no conflict of interest. TD received fees as a coordinator of the CCC. BF reports personal fees outside the submitted work from Inotrem, Biomérieux, AM-Pharma, Takeda, Enlivex, Aridis, GSK, Asahi-Kasai. JBL reported receiving consultation fees from Asahi Kasei America Corporation outside the submitted work. AB Consultancy fees from GSK and Danone Nutricia. DC has no conflict of interest. OH has no conflict of interest. JCL has no conflict of interest to declare. BC served as a member of an advisory board for Roche Diagnostics. JP has no conflict of interest with the present work. MB holds shares of SmartDyeLivery GmbH, Jena. He has received funding for scientific advisory boards, travel and speaker honoraria by T2 Biosystems, Inc., La Jolla Pharmaceutical Company, SNIPR BIOME Denmark, CytoSorbents GmbH, Thermo Fisher Scientific (B·R·A·H·M·S GmbH), Roche Diagnostics International Ltd., Transgene S.A. and SphingoTec GmbH. TG has non conflict of interest with the present work. MK reports grant support from Adrenomed and Vifor, and honoraria from Adrenomed, SphingoTec, Vifor, Amgen, 4TEEN4, Astra-Zeneca, and Sanofi. AM reports personal fees from Orion, Sanofi, Adrenomed, Epygon and Fire 1 and grants and personal fees from 4TEEN4, Abbott, Roche and SphingoTec.